MABC1709

Anti-Carcinoma Glycans Antibody, clone mAB-A4

clone mAb-A4, from mouse

• Synonyme(s) : Cancer Cell Glycans
• Code UNSPSC : 12352203
• Nomenclature NACRES : NA.41

Propriétés

• Source biologique: mouse
• Clone: mAb-A4, monoclonal
• Espèces réactives: human
• Technique(s): flow cytometry: suitable; immunohistochemistry: suitable; immunoprecipitation (IP): suitable; western blot: suitable
• Isotype: IgMκ
• Température de stockage: 2-8°C
• Modification post-traductionnelle de la cible: unmodified

Description

Description générale

Cancer cells contain distinctive glycan structures on their cell surface and their presence on glycoproteins or glycolipids can play a functional role in cancer progression. They are also important targets for cancer therapy. They can be targeted by monoclonal antibodies for detection and intervention. Clone mAb-A4 is shown to specifically bind only to glycans in breast, ovary, testis, lung, pancreas, bone and small intestine cancer cells, but not to benign cells in these tissues. Hence, it can be a useful tool to distinguish between malignant and benign cells. This antibody targets primarily N-linked glycans and bind to H-type I antigen (Fuc-alpha1,2-Gal-beta1,3-GlcNAc), with secondary binding to type I LacNAc. Removal of N-glycans, but not sialic acid, from the antigen using PNGaseF is shown to abolish the binding of this antibody. These antigens are also found to be pluripotency-associated antigens on human embryonic stem cells (hESC). This clone is shown to have a direct cytotoxic effect against hESC and SKOV3 ovarian cancer cells and cause significant reduction in their viability. (Ref.: Liau, B., et al. (2017). Sci. Rep. 7; 14489; Choo, M., et al. (2017). J. Biol. Chem. 292(15); 6163-6176).

Spécificité

Clone mAb-A4 detects ovarian and breast cancer cells and targets H Type 1 glycans.

Immunogène

Live HES-3 human embryonic stem cells.

Application

Immunoprecipitation Analysis: A representative lot immunoprecipitated Carcinoma Glycans in Immunoprecipitation applications (Choo, M., et. al. (2017). J Biol Chem. 292(15):6163-6176).Immunohistochemistry Analysis: A representative lot detected Carcinoma Glycans in Immunohistochemistry applications (Choo, M., et. al. (2017). J Biol Chem. 292(15):6163-6176).Flow Cytometry Analysis: A representative lot detected Carcinoma Glycans in Flow Cytometry applications (Liau, B., et. al. (2017). Sci Rep. 7(1):14489; Choo, M., et. al. (2017). J Biol Chem. 292(15):6163-6176).Western Blotting Analysis: A representative lot detected Carcinoma Glycans in Western Blotting applications (Liau, B., et. al. (2017). Sci Rep. 7(1):14489; Choo, M., et. al. (2017). J Biol Chem. 292(15):6163-6176).

Qualité

Evaluated by Flow Cytometry in BT-474 human breast carcinoma cells.Flow Cytometry Analysis: 1 µg of this antibody detected Carcinoma Glycans in one million BT-474 human breast carcinoma cells.

Forme physique

Purified mouse monoclonal antibody IgM in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Format: Purified

Purification Method: Protein G purified

Stockage et stabilité

Stable for 1 year at 2-8°C from date of receipt.

Autres remarques

Concentration: Please refer to lot specific datasheet.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.